Aura’s New CEO Inherits a 100-Patient Trial With 86 Already Enrolled
Natalie Holles is taking over Aura Biosciences at the exact point where its lead cancer program moves from fundraising story to execution test.
Aura said on May 4 that its board appointed Holles as chief executive and president effective April 30, replacing founder Elisabet de los Pinos, who will remain as a consultant through October. The same filing said Aura's Phase 3 CoMpass trial for belzupacap sarotalocan, or bel-sar, had enrolled 86 patients, with more than 25 additional patients scheduled or identified for screening through May, and that the company still expects enrollment to complete by mid-2026 with topline data in the second half of 2027 (SEC filing).
That makes the handoff unusually clean. Holles is not arriving to launch the study. She is arriving to finish it.
The public trial record shows why the number matters. CoMpass, registered as NCT06007690, is a randomized, masked Phase 3 study of bel-sar against sham control in primary indeterminate lesions or small choroidal melanoma. ClinicalTrials.gov still lists estimated enrollment at 100 patients, with the study recruiting, a Feb. 2026 verification date and the latest posted update on March 2, before Holles' appointment (ClinicalTrials.gov). Aura's older launch announcement described the same roughly 100-patient target and the 2:1:2 randomization across high-dose bel-sar, low-dose bel-sar and sham arms (Aura investor release).
In other words, the current public registry does not show a post-Handoff protocol reset. It shows a late-stage enrollment push. If Aura can turn 86 enrolled patients plus the May screening pool into full enrollment by midyear, Holles inherits a 2027 readout clock rather than a rescue job.
That is a different kind of biotech CEO change than the one happening at TORL BioTherapeutics. TORL said Aran Maree became CEO and board member on May 1, succeeding Mark Alles, who remains chairman, as the company advances ixotatug vedotin, its CLDN6 antibody-drug conjugate, toward first regulatory filings and expects registrational Phase 2 CATALINA-2 data in 2027 (PR Newswire). TORL also said it has raised more than $450 million from global biotechnology investors (PR Newswire).
Both moves are less about charismatic-founder theater than about whether specialist executives can carry late clinical programs through the unglamorous stretch before data. Holles previously led Third Harmonic Bio from August 2021 through December 2025, according to Aura's filing (SEC filing). Third Harmonic announced a liquidation plan in April 2025 after its board concluded the plan was the best way to maximize stockholder value (GlobeNewswire). That history gives the Aura appointment a sharper question: not whether Holles can sell a rare-disease story, but whether she can close enrollment and preserve investor patience until a binary oncology readout.
The immediate audit trail is straightforward. Aura's press release says 86 patients are already enrolled and more than 25 are in the near-term screening funnel. ClinicalTrials.gov still says the planned enrollment is 100. The company's guidance says completion by mid-2026 and data in the second half of 2027. Those three facts make the first KPI for the new CEO visible before any conference-stage narrative does.
For readers, that is the useful frame. The leadership change is news, but the operating story is the gap between a nearly enrolled trial and a data event that remains more than a year away. If Holles keeps CoMpass on the current public schedule, the CEO transition looks like a handoff at the finish line. If the timetable slips, the May 2026 appointment becomes the start of a much harder story.